Neuroscience

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech ConferenceProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the…

4 months ago
ONWARD Medical’s ARC-EX System Now Available on US Veterans Affairs Online Procurement PlatformsONWARD Medical’s ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms

ONWARD Medical’s ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms

ONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage…

4 months ago
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 202510x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

PLEASANTON, Calif., Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced…

4 months ago
KFSHRC Heart Centre: A Leader in Advanced Cardiac TreatmentsKFSHRC Heart Centre: A Leader in Advanced Cardiac Treatments

KFSHRC Heart Centre: A Leader in Advanced Cardiac Treatments

Revolutionizing care from minimally invasive surgery to comprehensive outpatient services RIYADH, Saudi Arabia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- King…

4 months ago
bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Typesbit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types

bit.bio Launches ioTracker Cells Range at SLAS 2025, Adding New Visualisation Functionality to Human iPSC-derived Cell Types

Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up…

4 months ago
Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric CareFirefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care

Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and…

4 months ago
America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent SearchAmerica’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration…

4 months ago
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet NeurologyFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalised myasthenia gravis published in The Lancet Neurology

The first investigational FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+,…

4 months ago
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

4 months ago